Shared on 30 Oct 25
Fair value Decreased 7.36%Narrative Update: NovoCure Analyst Price Target Adjusted Analysts have modestly reduced their price target for NovoCure from $27.19 to $25.19. They cite increased long-term conservatism in their latest models.
Shared on 01 Aug 25
Fair value Decreased 14%Regulatory Approvals And Global Launches Will Expand Oncology Reach
NovoCure’s fair value estimate fell as its future P/E multiple contracted notably and its discount rate increased, leading to a lower consensus analyst price target of $27.19. What's in the News NovoCure to present final secondary endpoint results from Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for unresectable, locally advanced pancreatic cancer at ESMO GI Cancers Congress 2025, focusing on quality of life outcomes and time to first opioid use.
Shared on 01 May 25
Fair value Decreased 5.23%Multi-indication Oncology Trials Will Open European Treatment Opportunities
Shared on 24 Apr 25
Fair value Decreased 4.18%Multi-indication Oncology Trials Will Open European Treatment Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 8.83%Multi-indication Oncology Trials Will Open European Treatment Opportunities
AnalystConsensusTarget has increased revenue growth from 8.5% to 9.5%.
Shared on 09 Apr 25
Fair value Decreased 11%Multi-indication Oncology Trials Will Open European Treatment Opportunities
Shared on 02 Apr 25
Fair value Increased 1.29%Multi-indication Oncology Trials Will Open European Treatment Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 9.08%Multi-indication Oncology Trials Will Open European Treatment Opportunities
AnalystConsensusTarget made no meaningful changes to valuation assumptions.